Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Growth Metrics
Income Statement
Others
Ratios

Applied Therapeutics (APLT) Net Cash Flow (2023 - 2025)

Historic Net Cash Flow for Applied Therapeutics (APLT) over the last 3 years, with Q3 2025 value amounting to -$18.5 million.

  • Applied Therapeutics' Net Cash Flow rose 2080.58% to -$18.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$86.9 million, marking a year-over-year decrease of 24154.37%. This contributed to the annual value of $29.5 million for FY2024, which is 1125.42% down from last year.
  • As of Q3 2025, Applied Therapeutics' Net Cash Flow stood at -$18.5 million, which was up 2080.58% from -$20.3 million recorded in Q2 2025.
  • In the past 5 years, Applied Therapeutics' Net Cash Flow registered a high of $96.6 million during Q1 2024, and its lowest value of -$28.6 million during Q1 2025.
  • For the 3-year period, Applied Therapeutics' Net Cash Flow averaged around -$428363.6, with its median value being -$18.5 million (2025).
  • The largest annual percentage gain for Applied Therapeutics' Net Cash Flow in the last 5 years was 144290.73% (2024), contrasted with its biggest fall of 136724.61% (2024).
  • Over the past 3 years, Applied Therapeutics' Net Cash Flow (Quarter) stood at $12.4 million in 2023, then crashed by 256.49% to -$19.5 million in 2024, then grew by 5.1% to -$18.5 million in 2025.
  • Its last three reported values are -$18.5 million in Q3 2025, -$20.3 million for Q2 2025, and -$28.6 million during Q1 2025.